Premier Retina Specialists​

10100 Loop 40 W, Midland, TX 79706  

432-617-0181

For Life-Threatening Emergencies Call 911

 

We are located down the street from Midland International Air and Space Port,

next door (west) to the Post Office.

Current Drug Research Studies being conducted at

Premier Retina Specialists

The ALTISSIMO Study

A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration.

Sponsor: Graybug Vision, Inc.
275 Shoreline Drive, Suite 450
Redwood City, CA 94065

Indication: Neovascular age-related macular degeneration (Wet Macular Degeneration)


Protocol Number (Phase): GBV-102-002 (Phase 2b)

Objectives: Primary Objective
To evaluate the safety and duration of the effect of GB-102, as measured by time to first rescue treatment across multiple dose levels
of GB-102 administered every 6 months as compared to intra-vitreal (IVT) aflibercept administered every 2 months in subjects with
neovascular (wet) age-related macular degeneration who have received prior induction with anti-vascular endothelial growth factor
(VEGF)

The PANDA Study

A Phase 3 Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intra-vitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (Wet

Macular Degeneration)

Sponsor:Chengdu Kanghong Biotechnology Co., Ltd.
108 Shuxi Road
Jinniu District
Chengdu 610036, China

Indication: Neovascular age-related macular degeneration (Wet Macular Degeneration)


Protocol Number (Phase): KHB-1802

Objectives: Primary Objective
To evaluate the efficacy and safety of 0.5 mg and 1.0 mg conbercept IVT injection compared with the vascular endothelial growth factor (VEGF) antagonist active control, aflibercept IVT injection (2.0 mg, Eylea®, Regeneron Pharmaceuticals, Inc., Bayer AG), in subjects with neovascular age-related macular degeneration (AMD).

For further information about studies, please contact the practice and speak to Lu An, the Clinical Trial Director, at extension 201.